Hemostemix
Announces
Completion
of Phase II Clinical Trial Subject
Follow
Up & HMTXF Up-list
Calgary, Alberta,
April 23,
2021--
InvestorsHub NewsWire -- Hemostemix Inc. ("Hemostemix"
or the "Company")
(TSXV: HEM) (OTC: HMTXF) (FSE:2VFO.F)
is
pleased to announce the completion of
the Phase II Clinical Trial subject
follow
up, as the
65th
(final)
subject
has completed their
last
follow-up visit. With subject follow
up now completed the Company is shifting its focus to completing
the data analyses and reporting associated with finalizing
their Phase II Clinical Trial. In
addition,
the Company has
contracted two additional clinical research associates to assist
with the completion of the source document verification
process. The entry of all
subjects' information into the clinical trial data base and source
document verification processes are ongoing and this is a
crucial preliminary step in finalizing the Phase II Clinical
Trial.
Today, FINRA processed a Form 211 relating to the initiation of
priced quotations
of HMTXF
on OTCQB,
where the Company has reapplied to be listed.
The
submitting broker-dealer has demonstrated to FINRA compliance with
FINRA Rule 6432 and
has met the requirements under that rule to initiate
quotation
of
HMTXF within three
business
days.
FINRA's processing of a Form 211 in no way constitutes FINRA's
approval of the security, the issuer, or the issuer's business and
relates solely to the submitting broker-dealer's obligation to
comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a
security.
On
April
20, 2021, the United
States District Court for the District of Delaware
received
Aspire
Health Sciences, LLC's defence
statements.
ABOUT HEMOSTEMIX
Hemostemix is a publicly traded
autologous stem cell therapy company. A winner of the World
Economic Forum Technology Pioneer Award, the Company developed and
is commercializing its lead product ACP-01 for the treatment of
CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy
and other conditions of ischemia. ACP-01 has been used to treat
over 300 patients, and it is the subject of a randomized,
placebo-controlled, double blind trial of its safety and efficacy
in patients with advanced critical limb ischemia who have exhausted
all other options to save their limb from amputation.
On
October 21, 2019, the Company announced the
results from its Phase II CLI trial abstract entitled "Autologous
Stem Cell Treatment for CLI Patients with No Revascularization
Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year
Followup" which noted healing of ulcers and resolution of ischemic
rest pain occurred in 83% of patients, with outcomes maintained for
up to 4.5 years.
The Company owns 91
patents across five patent families titled: Regulating Stem Cells,
In Vitro Techniques for use with Stem Cells, Production from Blood
of Cells of Neural Lineage, and Automated Cell Therapy. For more
information, please visit www.hemostemix.com.
Contact: Thomas Smeenk, President, CEO
& Co-Founder
TSmeenk@Hemostemix.com
905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined under the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Information: This
news release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. All
statements, other than statements of historical fact, included
herein are forward-looking information. In
particular, this news
release contains
forward-looking information in relation to: the completion of the
follow-up for Hemostemix's ACP-01 clinical trial and the source
document verification process the status of Hemostemix's Litigation
(as defined below); and the commercialization of ACP-01.
There
can be no assurance that such forward-looking information will
prove to be accurate. Actual results and future events could differ
materially from those anticipated in such forward-looking
information. This
forward-looking information reflects Hemostemix's current beliefs
and is based on information currently available to Hemostemix and
on assumptions Hemostemix believes
are reasonable. These
assumptions include, but are not limited to: the underlying value
of Hemostemix and its Common Shares; market
acceptance of the Offerings; Exchange acceptance of the
Offerings; the
successful resolution of the litigation that Hemostemix is pursuing
or defending (the "Litigation");
the results of ACP-01 research, trials, studies and analyses,
including the midpoint analysis, being equivalent to or better than
previous research, trials or studies as well as management's
expectations
of anticipated results; Hemostemix's general and administrative
costs remaining constant; the receipt of all required
regulatory approvals
for research, trials or studies; the level of activity, market
acceptance and market trends in the healthcare sector; the
economy
generally; consumer interest
in Hemostemix's services and products; competition and
Hemostemix's
competitive advantages; and Hemostemix obtaining satisfactory
financing to fund
Hemostemix's operations including any research, trials or studies,
and the Litigation. Forward-looking
information is subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of Hemostemix to be
materially different from those expressed or implied by such
forward-looking information. Such risks and other factors may
include, but are not limited to: the ability of Hemostemix to
complete its current CLI clinical trial, complete a satisfactory
analyses and the results of such analyses and future
clinical trials; litigation
and potential litigation that Hemostemix may face; general
business, economic, competitive, political and social
uncertainties; general capital market conditions and market prices
for securities; delay or failure to receive board or regulatory
approvals; the
actual results of future operations including
the actual results of future research, trials or
studies; competition;
changes in legislation affecting
Hemostemix; the timing and availability of external financing on
acceptable terms; long-term capital requirements and future
developments in Hemostemix's markets and the markets in which it
expects to compete; lack
of qualified, skilled labour or loss of key individuals; and
risks related
to the COVID-19 pandemic including various recommendations, orders
and measures of governmental authorities to try
to limit the pandemic, including travel restrictions, border
closures, non-essential business closures, service
disruptions, quarantines, self-isolations, shelters-in-place and
social distancing, disruptions to markets, disruptions to economic
activity and financings,
disruptions to supply chains and sales channels, and a
deterioration of general economic conditions including a
possible
national or global recession or depression; the
potential impact that the COVID-19 pandemic may have on Hemostemix
which may include a decreased demand for the services that
Hemostemix offers;
and a deterioration of financial markets that could limit
Hemostemix's ability to obtain external financing. A description of
additional risk factors that may cause actual results to differ
materially from forward-looking information can be found in
Hemostemix's disclosure documents on the SEDAR website at
www.sedar.com. Although Hemostemix has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking information,
there may be other factors that cause results not to be as
anticipated, estimated or intended. Readers
are cautioned that the foregoing list of factors is not
exhaustive. Readers
are further cautioned not to place undue reliance on
forward-looking information as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Forward-looking information contained in this news release
is expressly qualified by this cautionary statement. The
forward-looking information contained in this news release
represents the expectations of Hemostemix as of the date of this
news release and, accordingly, it is subject to change after such
date. However, Hemostemix expressly disclaims any intention or
obligation to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable securities
law.